Carl R. Merril+, Mark P. Goldstein+, James E. Myrick*, G. Joseph Creed+, and Peter F. Lemkin@
Note: See the second part of these 2 part papers The Protein Disease Database of human body fluids: II. Computer methods and data issues
Keywords: electrophoresis; gel; two-dimensional; human; database; protein; disease; body fluids; electrophoretic; diagnostic; Alzheimer's disease; schizophrenia; acute phase proteins; serum; plasma; urine; cerebrospinal fluid
The need for such databases became apparent soon after the development of high resolution two-dimensional protein electrophoresis (2-DE). In a study of lymphocyte proteins from Lesch-Nyhan patients, conducted soon after the introduction of 2-DE, it became apparent that numerous proteins might be affected even in diseases caused by a single gene mutation. As the Lesch-Nyhan syndrome is caused by a mutation in the gene for hypoxanthine phosphoribosyltransferase (HGPRTase), one might expect a change only in the protein spot representing HGPRTase. However, 2-DE demonstrated 11 additional proteins that were quantitatively affected by a factor of 2 or more in this syndrome (Merril et al., 1981). In addition, early investigators studying this syndrome had found altered enzyme activities for 5 other enzymes involved with purine metabolism in tissues for Lesch-Nyhan patients. These studies suggested that the ability to quantitatively analyze and collate large numbers of protein changes in disease states could be useful diagnostically and could provide additional insights into the underlying pathophysiology. In addition, while more traditional linear literature search methods may have sufficed when proteins were first being identified, the enormous number of proteins now detectable by a wide variety of methods makes it critical to employ modern, networked computers for the analysis of such data.
From the first recognition of proteins by Gerardus J. Mulder in 1836, progress in resolving and identifying them has been growing at an exponential rate (Figure 1). By 1937, Tiselius was able to separate serum globulin into a, b and g components (Tiselius, 1937). By 1956, Smithies and Poulik were able to resolve 20 proteins (Smithies & Poulik, 1956) and in 1969, Freeman and Smith were able to resolve over 60 distinct serum proteins (Freeman & Smith, 1970). By 1977, Anderson and Anderson, using 2-DE, identified over 300 serum proteins (Anderson & Anderson, 1977), and now Hochstrasser and his colleagues have increased the number of proteins visualized in plasma to 2,500 (Hochstrasser, 1995). In addition, over the same period of time research and clinical applications of analytical protein methods have generated a vast body of information in the biomedical literature pertaining to plasma, serum, CSF and urinary protein changes in disease states, including toxicant exposures. The protein content of these body fluids is not independent, in that proteins in urine and CSF are mainly the products of filtration of the plasma. While much of the data in the database described here were gathered by non-electrophoretic methods, we have adopted the model provided by high resolution 2-DE of arraying the proteins of the body fluid in two dimensions, one for the pI and the other for the molecular weight, with a third dimension to portray quantitative information. This format will, as the database is developed, allow graphic representation of quantitative protein changes in disease or toxicant-exposed states. The conversion and collation of information concerning these body fluids into a useful database will require the cooperative efforts of researchers throughout the biomedical community, including both those with computer expertise and those with clinical experience.
Given the above problems, the database presented here normalizes data from independent studies by converting quantitative protein values into a dimensionless quantity, expressed as a concentration and/or activity fold change, in which the fold change for each protein is defined as the mean of the disease values/mean of the normal values. While this approach can be used to normalize data from independent studies, users of the database must be careful to assure that the methods utilized in the independent studies are equivalent with respect to a disease state (as noted above). In addition, the database tracks and displays the methods used in each study so that users of this database can judge for themselves as to whether the data from the independent studies under consideration can be compared in a meaningful manner. This normalization scheme is discussed in greater detail in the accompanying paper (Lemkin et al., 1995).
Future plans also include depicting the quantitative changes of all proteins associated with each disease visually on the appropriate electrophoretogram. This visual cue will be extended into the third dimension of the 2-D gel for each protein which increases with the pathology. A second query will result in the same third dimension cue for each protein which decreases with the pathology.
The finding of common acute phase response protein variations in the serum and CSF proteins in patients with mental disorders such as schizophrenia, manic depressive disease, and Alzheimer's disease may provide some insight into some of the underlying pathophysiology of these diseases. For example, it is known that the acute phase response includes the activation of immunocompetent cells such as macrophages, monocytes and lymphocytes when these cells are exposed to antigens, toxins and products of cell injury (Dunn, 1991). These activated immunocompetent cells secrete cytokines (Dunn, 1991; Dinarello & Wolff, 1993) which initiate hepatic acute phase protein synthesis and secretion (Heinrich et al., 1990; Koj et al., 1993; Kushner and Mackiewicz, 1993). In addition, the elevation of these cytokine levels can have deleterious effects both directly and indirectly on neuronal cells and behavior (Figure 4).
While many of the complex correlations between diseases and proteins in the example described above were found by carefully reviewing the extensive literature of plasma, serum and CSF proteins, if a database such as the one which we are constructing were available, the task would have been much easier. In addition, since techniques such as high resolution two-dimensional electrophoresis permit researchers to quantitatively observe thousands of proteins in a single sample of a body fluid, it would be useful to know which diseases are associated with the protein variations observed in the electrophoretogram from the current patient of interest. Conversely, if one had reason to suspect a patient had a specific disease, the protein alterations observed could help to confirm the diagnosis. In addition, since the PDD is dynamically linked to other protein databases such as SWISS-PROT, once a protein is identified as of interest, it's possible to determine it's structural and physiological functions, if they are known. This information may prove useful for an understanding of underlying pathophysiology.
It is our hope that the Protein Disease Database will prove useful for many applications. In this regard it should be noted that data currently being entered are being culled from the peer reviewed literature. In some cases the number of observations are limited and there are some which appear to be in contradiction. For these reasons the current database is intended only for research applications.
2. Altstiel, L. & Sperber, K. (1991). Cytokines in Alzheimer's disease. Prog. Neuro-Psychopharmacol. & Bio. Psychiat. 15, 481-495.
3. Anderson, L. & Anderson, N.G. (1977). High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl. Acad. Sci. USA 74, 5421-5425.
4. Barna, B.P., Estes, M.L., Jacobs, B.S., Hudson, S. & Ransohoff, R.M. (1990). Human astrocytes proliferate in response to tumor necrosis factor alpha. Journal of Neuroimmunology 30, 239-243.
5. Behan, P.O. & Feldman, R.G. (1970). Serum proteins, amyloid and Alzheimer's disease. J. of the American Geriatrics Society 18, 792-797.
6. Bock, E., Weeke, B. & Rafaelsen, O. (1971). Serum proteins in acutely psychotic patients. Journal of Psychiatric Research 9, 1-9.
7. Brugge, K., Katzman, R., Hill, L.R., Hansen, L.A. & Saitoh T. (1992). Serological alpha-1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann. Neurol. 32, 193-197.
8. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D. & Rosenberg, S.A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine 107, 293-300.
9. Dinarello, C.A. & Wolff, S.M. (1993). The role of interleukin-1 in disease. N. Engl. J. Med. 328, 106-113.
10. Dunn, C.J. (1991). Cytokines as mediators of chronic inflammatory disease. In Kimball, E.S., (ed) Cytokines and Inflammation. Boca Raton, Florida: CRC Press, Inc., pp 1-33.
11. Freeman, T. & Smith, J. (1970). Human serum protein fractionation by gel filtration. Biochem. J. 118, 869-873.
12. Gammack, D.B. & Hector, R.I. (1965). A study of serum proteins in acute schizophrenia. Clin. Sci. 28, 469-475.
13. Giometto, B., Argentiero, V., Sanson, F., Ongaro, G. & Tavolato, B. (1988). Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 28, 30-33.
14. Goldgaber, D., Harris, H.W., Hla, T., Maciag, T., Donnelly, R.J., Jacobsen, J.S., Vitek, M.P. & Gajdusek, D.C. (1989). Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86, 7606-7610.
15. Hancock, K. & Tsang, V.C.W. (1983). India ink staining of proteins on nitrocellulose paper. Anal. Biochem. 133, 157-162.
16. Harrington, M.G., Merril, C.R. & Torey, E.F. (1985). Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons. Clin. Chem. 31, 722-726.
17. Heinrich, P.C., Castell, J.V. & Andus, T. (1990). Interleukin-6 and the acute phase response. Biochem. J. 265, 621-636.
18. Hermus, A.R.M.M. & Sweep, C.G.J. (1990). Cytokines and the hypothalamic-pituitary-adrenal axis. J. Steroid Biochem. Molec. Biol. 37, 867-871.
19. Hochstrasser, D.F. (1995). Personal Communication. 20. Johnson, G., Brane, D., Block, W., van Kammen, D., Gurklis, J., Peters, J., Wyatt, R., Kirch, D., Ghanbari, H. & Merril, C. (1992). Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl. and Theor. Electrophoresis 3, 47-53.
21. Joyce, P.R., Hawes, C.R., Mulder, R.T., Sellman, J.D., Wilson, D.A. & Boswell, D.R. (1992). Elevated levels of acute phase plasma proteins in major depression. Biol. Psychiatry 32, 1035-1041.
22. Koj, A., Gauldie, J. & Baumann, H. (1993). Biological perspectives of cytokine and hormone networks. In Mackiewicz, A., Kushner, I. & Baumann, H. (eds), Acute Phase Proteins - Molecular Biology, Biochemistry and Clinical Applications. Boca Raton, Florida, CRC Press, Inc., pp 275-287.
23. Kushner, I. (1982). The phenomenon of the acute phase response. Ann. NY Acad. Sci. 389, 39-48.
24. Kushner, I. & Mackiewicz, A. (1987). Acute phase proteins as disease markers. Disease Markers 5, 1-11.
25. Kushner, I. & Mackiewicz, A. (1993). The acute phase response: an overview. In Mackiewicz, A., Kushner, I. & Baumann, H. (eds). Acute Phase Proteins - Molecular Biology, Biochemistry and Clinical Applications. Boca Raton, Florida, CRC Press, Inc., pp 3-19.
26. Lemkin, P.F., Orr, G.A., Goldstein, M.P., Creed, G.J., Myrick, J.E. & Merril, C.R. (1995). The Protein Disease Database of human body fluids: II. Computer methods and data issues. Appl. and Theor. Electrophoresis 5, 12-57.
27. Maes, M., Scharpe, S., Van Grootel, L., Uyttenbroeck, W., Cooreman, W., Cosyns, P. & Suy, E. (1992a). Higher alpha-1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: Further evidence for the existence of an inflammatory response during that illness. Journal of Affective Disorders 24, 183-192.
28. Maes, M., Scharpe, S., Bosmans, E., Vandewoude, M., Suy, E., Uyttenbroeck, W., Cooreman, W, Vandervorst, C. & Raus, J. (1992b). Disturbances in acute phase plasma proteins during melancholia: Additional evidence for the presence of an inflammatory process during that illness. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 16, 501-515.
29. Manchenko, G.P. (ed.) (1994). Handbook of Detection of Enzymes on Electrophoretic Gels. Boca Raton, Florida, CRC Press, Inc.
30. Matsubara, E., Hirai, S., Amari, M., Shoji, M., Yamaguchi, H., Okamoto, K., Ishiguro, K., Harigaya, Y. & Wakabayashi, K. (1990). Alpha-1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 28, 561-567.
31. Merril, C.R., Goldman, D. & Ebert, M. (l98l). Protein variations associated with the Lesch-Nyhan syndrome. Proc. Natl. Acad. Sci. USA 78, 6471-6475.
32. Rada, P., Mark, G.P., Vitek, M.P., Mangano, R.M., Blume, A.J., Beer, B. & Hoebel, B.G. (1991). Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Research 550, 287-290.
33. Scheele, G.A. (1982). Two-dimensional electrophoresis in basic and clinical research, as exemplified by studies on the exocrine pancreas. Clin. Chem. 28, 1056-1061.
34. Schienberg, I.M., Morell, A.G., Harris, R.S. & Berger, A. (1957). Concentration of ceruloplasmin in plasma of schizophrenic patients. Science 126, 925-927.
35. Selmaj, K.W., Farooq, M., Norton, W.T., Raine, C.S. & Brosnan, C.F. (1990). Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 144, 129-135.
36. Selmaj, K.W., Raine, C.S., Farooq, M., Norton, W.T. & Brosnan, C.F. (1991). Cytokine cytotoxicity against oligodendrocytes -- Apoptosis induced by lymphotoxin. J. Immunol. 147, 1522-1529.
37. Smithies, O. & Poulik, M.D. (1956). Two-dimensional electrophoresis of serum proteins. Nature 176, 1256-1266.
38. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. & Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916.
39. Symons, R.H. (l992). Small catalytic RNAs. Annu. Rev. Biochem. 61, 641-671.
40. Tiselius, A. (1937). Electrophoresis of serum globulin. I. Biochem. J. 31, 313-317.
41. Wildenauer, D.B., Korschenhausen, D., Hoechtlen, W., Ackenheil, M., Kehl, M. & Lottspeich, F. (1991). Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two-dimensional electrophoresis: Identification of disease-associated polypeptides as fibrin fragments. Electrophoresis 12, 487-492.
Figure 1. Number of serum proteins detected since 1838. Advances in electrophoretic methodology since 1950, have resulted in an exponential growth in the number of proteins which can be detected in physiological fluids.
Figure 2.
Electrophoretogram of 300 micro-liter of concentrated CSF.
The locations of a-2-haptoglobin and two fibrin fragments
(proteins 127 and 128), which increase in both schizophrenia and
Alzheimer's disease, are identified, as well as, several other marker
proteins. The electrophoretogram is presented in an embossed format
to emphasize that the PDD contributes a third, quantitative dimension
to the data being collected. Future development of the database will
include 3-D visual cues in such an electrophoretogram, depicting the
quantitative changes in all proteins associated with a given
disease.